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Abstract
Glioblastoma (GBM) is a highly lethal brain tumor presenting as one of two subtypes with distinct
clinical histories and molecular profiles. The primary GBM subtype presents acutely as high-grade
disease that typically harbors EGFR, Pten and Ink4a/Arf mutations, and the secondary GBM
subtype evolves from the slow progression of low-grade disease that classically possesses PDGF
and p53 events1–3. Here, we show that concomitant CNS-specific deletion of p53 and Pten in the
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tmouse CNS generates a penetrant acute-onset high-grade malignant glioma phenotype with
striking clinical, pathological and molecular resemblance to primary GBM in humans. This
genetic observation prompted p53 and Pten mutational analysis in human primary GBM,
demonstrating unexpectedly frequent inactivating mutations of p53 as well the expected Pten
mutations. Integrated transcriptomic profiling, in silico promoter analysis and functional studies of
murine neural stem cells (NSCs) established that dual, but not singular, inactivation of p53 and
Pten promotes an undifferentiated state with high renewal potential and drives elevated c-Myc
levels and its associated signature. Functional studies validated increased c-Myc activity as a
potent contributor to the impaired differentiation and enhanced renewal of p53-Pten null NSCs as
well as tumor neurospheres (TNSs) derived from this model. c-Myc also serves to maintain robust
tumorigenic potential of p53-Pten null TNSs. These murine modeling studies, together with
confirmatory transcriptomic/promoter studies in human primary GBM, validate a pathogenetic
role of a common tumor suppressor mutation profile in human primary GBM and establish c-Myc
as a key target for cooperative actions of p53 and Pten in the regulation of normal and malignant
stem/progenitor cell differentiation, self-renewal and tumorigenic potential.
High-grade malignant glioma, the most common intrinsic brain tumor, is uniformly fatal
despite maximum treatment3. A wealth of molecular genetic studies have established central
roles of the RTK-PI3K-PTEN, ARF-MDM2-p53, and INK4a-RB pathways in
gliomagenesis3, 4. To explore the role of p53 and Pten in glioma, we utilized the hGFAP-Cre
transgene5, 6 to delete p53 alone or in combination with Pten in all CNS lineages using
conditional p537 and Pten alleles (Supplementary Fig. 1, 2a-c). Since broad CNS deletion of
Pten results in lethal hydrocephalus in early postnatal life (data not shown), modeling efforts
henceforth emphasized the Ptenlox/+ genotype.
Clinically, between ages 15 to 40 weeks, 42/57 (73%) of hGFAP-Cre+;P53lox/lox;Ptenlox/+
mice presented with acute-onset neurological symptoms – seizure, ataxia, and/or paralysis
(Fig. 1a). Histopathologically, all 42 neurologically symptomatic mice harbored malignant
gliomas that, based on WHO criteria8, were classified as anaplastic astrocytomas (WHO III,
n=28, 66%) or GBM (WHO IV, n=14, 34%) (Fig. 1b) with classical features of
pseudopalisading necrosis, marked cellular pleomorphism, and highly infiltrative spread
including perineuronal and perivascular satellitosis as well as subpial spread in the cerebral
cortex (Supplementary Fig. 3a). Occasional tumors exhibited abnormal vessels suggestive of
microvascular proliferation. All tumors exhibited increased mitoses (Ki67 staining) and
expression of classical human glioma markers, GFAP and Nestin (Fig. 1c). Necropsy of 15
neurologically asymptomatic mice showed no cases of incipient low-grade glioma disease
but rather 8 with high-grade pathology including very small lesions with anaplastic features
of nuclear atypia, multinucleated tumor cells, and/or high cellularity (Supplementary Fig.
3b). For the remaining genotypes, 4/23 hGFAP-Cre;P53lox/lox mice developed anaplastic
astrocytoma (WHO III); whereas 19/23 hGFAP-Cre;P53lox/lox, 12/12 hGFAP-
Cre;P53lox/+;Ptenlox/+, and 10/10 hGFAP-Cre;P53lox/+) had no CNS pathology and
developed only non-CNS tumors (data not shown).
Historically, p53 inactivation has been considered a classical lesion in low-grade
astrocytomas and secondary GBM, but infrequent in primary GBM1, 9. The remarkable
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tclinical and histological resemblance of this model to the primary GBM subtype in humans
prompted p53 and Pten re-sequencing in human primary GBM. Of 35 clinically annotated
human primary GBM samples, 10/35 (29%) tumors registered prototypical p53 mutations
and 14/35 (40%) tumors possessed Pten missense mutations, insertions, deletions, or
splicing mutations (Supplementary Table 1). Moreover, 6/10 tumors with p53 mutations
harbored concomitant Pten mutations or homozygous deletion. Encouragingly, our
mutational data agrees with The Cancer Genome Atlas data reporting p53 and Pten as the
two most commonly mutated tumor suppressor genes (http://tcga-data.nci.nih.gov/tcga/
findArchives.htm). These results, together with recent population-based studies10, 11,
indicate that p53 is a key tumor suppressor for both GBM subtypes.
Consistent with frequent Pten LOH (60–70%) in human high-grade glioma3, 16/16 mouse
high-grade glimoas showed no Pten expression in tumor cells but robust signal in
surrounding non-malignant cells and intratumoral vessels (Fig. 2a). PCR geneotyping
indicated that 6/7 tested tumors sustained loss of the wild-type Pten allele (Fig. 2b). The
Pten reduction to homozygosity, and documented Cre-mediated deletion of both p53 floxed
alleles indicate that inactivation of both genes is required for gliomagenesis. Loss of Pten
expression correlated with activation of key PI3K signaling surrogates, AKT and S6-Kinase
(Fig. 2c). In accordance with human high-grade disease, 8/8 malignant murine gliomas
expressed high VEGF levels relative to normal brain tissue (Fig. 2c). Multi-RTK co-
activation in human primary GBM12 was also evident in the murine tumors with robust
PDGFRα expression overlapping with strong regional activation of EGFR (Supplementary
Fig. 4a-d)
A classical feature of human high-grade malignant glioma is a significant degree of inter-
and intra-tumoral morphological and lineage heterogeneity, hence the moniker glioblastoma
‘mutliforme’. This characteristic plasticity was evident in the hGFAP-
Cre;P53lox/lox;Ptenlox/+ gliomas wherein occasional tumors (5/50) presented with both
astrocytic and oligodendroglial histopathological features (Supplementary Fig. 5). The basis
for morphological variability is not known and may relate, among many possibilities, to
acquisition of an immature developmental state with multipotency and/or differentiative
plasticity. Consistent with this notion, all murine tumors express stem or lineage progenitor
markers including Nestin, GFAP, and Olig2 similar to human glioma profiles13, but
negative for mature neuronal and oligodendrocyte markers, NeuN and MBP (Supplementary
Fig. 6a-b). This stem/progenitor marker profile is in accord with the ability of all murine
tumors tested to readily generate tumor neurospheres (TNS) with (i) strong tumor-initiating
potential with secondary tumors faithfully retaining the primary tumor’s histological
features (Supplementary Fig. 7) (ii) robust NSC marker Nestin expression, and (iii) limited
capacity to differentiate into astrocytic and neuronal lineages upon exposure to
differentiation agents (Fig. 2d). As NSC/progenitor cells have been proposed to be the
preferred cell-of-origin for GBM6, the immature marker profile and varied morphological
presentation of our murine tumors prompted us to posit that Pten and p53 deficiencies might
contribute to gliomagenesis by affecting NSC self-renewal and differentiation potential.
To explore this hypothesis, we characterized primary murine E13.5 NSC cultures singly or
doubly null for p53 and Pten. Compared to Pten or p53 null NSCs which show only
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tmodestly increased proliferation and self-renewal reflected by neurosphere formation
capacity14–16, NSCs null for p53 and Pten exhibited significant proliferation and self-
renewal activity (Fig. 3a; Supplementary Fig. 8a). This impact on NSC renewal, coupled
with the aforementioned varied tumor histology, suggest that combined p53 and Pten loss
might cooperate in tumorigenesis by impairing NSC differentiation potential. When NSCs
were continuously cultured in NSC medium, all gentoypes showed similar robust expression
of NSC/progenitor markers (Nestin) and minimal expression of differentiated lineage
markers (Supplementary Fig. 8b). Upon exposure to differentiation-inducing medium, wild-
type and single-null NSC cultures differentiated into GFAP-positive astrocytes, Tuj1-
positive neurons, or O4-positive oligodendrocytes. In contrast, NSCs null for both p53 and
Pten failed to respond to these differentiation cues and retained stem cell-like morphology
and lineage marker (Nestin) expression (Fig. 3b; Supplementary Fig. 9a). Similar
differentiation defect and abnormal self-renewal potential were also observed in adult NSCs
that were deleted for Pten and p53 postnatally (Supplementary Fig. 9b, c). The contribution
of Pten deficiency in maintaining impaired differentiation was further verfied by the ability
of the AKT inhibitor, Triciribine17, to enable differentiation of Pten/p53 null NSCs
(Supplementary Fig. 10a, b).
To understand the molecular basis of impaired differentiation capacity, we performed
transcriptome comparisons of p53-null and p53/Pten double-null murine NSCs at 1 day post
exposure to the differentiation inducer. Among the 410 genes exhibiting significant
differential expression (Supplementary Table 2), promoter analysis identified E2F and MYC
motifs as two of the most enriched promoter binding elements (BE) (1.7x and 1.4x,
respectively; P < 10−4). Remarkably, promoter analysis using 69 pre-treatment human
primary GBM cases in the TCGA database showed strong enrichment of Myc binding
elements – 10 p53/Pten mutant tumors versus the 59 remaining tumors (1.40x, p=2.20x10−3)
or versus the 12 p53 only mutant tumors (1.46x, p=1.54x10−3).
c-MYC is well-known for its roles in cell cycle progression and apoptosis18 as well as stem
cell self-renewal and differentiation during development and oncogenic processes19–22. It is
also notable that both p53 and Pten/PI3K pathways can directly regulate c-Myc with p53
repressing c-MYC transcription through direct binding to c-MYC promoter23, while
downstream PI3K pathway arms can modulate c-MYC translation and protein
degradation24, 25. In agreement, c-Myc protein levels were substantially increased in the
murine double-null NSCs, but only marginally elevated in single p53-null or Pten-null NSCs
when compared to wild-type controls (Fig. 3c), raising the possibility that p53 and Pten
cooperate to regulate c-Myc levels which in turn could control NSC self-renewal and
differentiation.
To test this hypothesis, we examined the impact of c-Myc knockdown on murine p53/Pten-
null NSC differentiation potential and observed that c-Myc shRNAs (#2 and #3), which
reduced c-Myc levels to those in p53-null NSCs, largely restored their differentiation
capacity (Fig. 3d; Supplementary Fig. 11a). Conversely, enforced c-Myc expression in p53-
null NSCs repressed their differentiation and enabled retention of stem/progenitor marker
expression (Nestin and Sox2) (Supplementary Fig. 11b), indicating that concomitant loss of
p53 and Pten elevates c-MYC activity to impede NSC differentiation capacity.
Zheng et al. Page 4
Nature. Author manuscript; available in PMC 2014 June 10.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tThe strong pleiotropic activities attributed to c-MYC demands tight control of its expression
to avoid development of diverse human malignancies, including gliomas21, 26. Our finding
that concomitant loss of p53 and Pten compromised NSC differentiation capacity via
elevated c-Myc levels prompted further assessment of its relevance in the so-called ‘brain
cancer stem cells’ in our model. Using murine TNSs which are enriched for such tumor
initiating cells (TICs), AKT inhibitor treatment strongly reduced c-MYC protein and
promoted differentiation (Fig. 4a, b; Supplementary Fig. 12a). Correspondingly, c-Myc
knockdown in TNS cells not only markedly reduced their proliferation and self-renewal
capacity (Fig. 4c; Supplementary Fig. 12b, c), but also strongly sensitized them to
differentiation induction (Fig. 4d; Supplementary Fig. 12d). Importantly, while 10/10
intracranial injections of vector-transduced murine TNSs resulted in lethal infiltrating
gliomas within 1 month, 9/10 mice injected with c-Myc knockdown TNSs survived for more
than 3 months (Fig. 4e). Thus, c-MYC plays a key role in the maintenance of impaired
differentiation and potent tumorigenic potential of TNSs inactivated for p53 and Pten
(Supplementary Fig. 13).
The identification of TICs with stem-like properties in diverse human cancers including
GBM represents an important conceptual advance in cancer biology with therapeutic
implications27, 28. These TICs appear to constitute a reservoir of self-sustaining cells with
potent tumorigenic potential. However, unlike normal NSCs which readily differentiate
along a developmental hierarchy into lineage-restricted differentiated progenies, TNSs
derived from p53/Pten-null malignant gliomas show resistance towards differentiation cues.
The diminished tumorigenicity of these TICs upon restoration of differentiation potential,
along with recent reports supporting pro-differentiation as a potential strategy to inhibit
GBM-derived TICs29, 30, encourages the identification and testing of agents targeting these
differentiation pathways including c-Myc in the treatment of primary GBM in humans.
Full Methods
Mice
P53L and hGFAP-Cre mice have been described previously5, 7. PtenL mice were generated
using a standard knock-in approach in which Pten exon 5 is flanked by loxP sites (details on
targeting construct and procedures are available upon request). Mice were interbred and
maintained on FvB/C57Bl6 hybrid background in pathogen-free conditions at Dana-Farber
Cancer Institute, monitored for signs of ill-health every other day, and euthanized and
necropsied when moribund. All manipulations were performed with IACUC approval.
Histology and Immunohistochemistry
At time of sacrifice, mice were perfused with 4% paraformaldehyde (PFA), and brains were
dissected, followed by overnight post-fixation in 4% PFA at 4°C. Serial sections were
prepared at 5 µm for paraffin sections or 10 µm for cryostat sections with every tenth slide
stained by haematoxylin and eosin (DF/HCC Research Pathology Cores). Tumor grading
was determined by K.L.L and H.Z. based upon the WHO grading system for malignant
astrocytoma8. Immunohistochemical and immunofluorescence analyses were performed as
described31. The PDGFRα/pEGFR double immunohistochemical staining was performed
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tusing DakoCytomation EnVision doublestain system (K1395, Dako) following
manufacturer instructions. The primary antibodies used were: Ki67 (VP-RM04, Vector),
GFAP (Z0334, DAKO), GFAP (556330, BD Pharmingen), Nestin (MAB353, Chemicon;
specifically for mouse), Nestin (MAB5326, Chemicon; specifically for human), Pten (9559,
Cell Signaling), Phospho-AktSer473 (3787, Cell Signaling), phospho-S6 ribosomal protein
(2215, Cell Signaling), Cyclin D1 (18-0220, ZYMED), VEGF (sc-152, Santa Cruz),
PDGFRα (3174, Cell Signaling), Phospho-PDGFRaY754 (sc-12911, Santa Cruz), EGFR
(IHC-00005, Bethyl), Phospho-EGFRY1068 (ab40815, Abcam), Phospho-EGFRY1173
(sc-12351, Santa Cruz), Olig-2 (AB9610, Chemicon), TUJ-1 (MMS-435P, Covance), O4
(MAB1326, R&D), NeuN (MAB377, Millipore), MBP (ab7349, Abcam), c-Myc (ABcam,
ab39688), and Cre (69050-3, Novagen). Images were captured using a Leica DM1400B
microsystem and Leica FW4000 version 1.2.1.
Cell culture
Primary NSCs were isolated from the brain subventricular zone (SVZ) of E13.5 embryos or
1 month old mice with the indicated genotype as previously described31, 32. NSCs were
maintained in NSC proliferation media (05702, StemCell) supplemented with 20 ng/mL
EGF (E4127, Sigma) and 10ng/mL bFGF (F0291, Sigma). To generate primary TNS cells,
tumor samples from freshly dissected mouse brains were subjected to mechanical and
enzymatic dissociation. Single-cell suspensions were cultured in NSC proliferation media.
Tumor spheres formed were then disaggregated and used for indicated assays. NSC
differentiation assays were carried out by plating the indicated cells in culture wells on
coverslips pre-coated with 15 µg/mL poly-L-ornithine (P3655, Sigma) and 1 µg/mL
fibronectin (F1141, Sigma); the cells were incubated in neurobasal medium supplemented
with 1% FBS for 7–10 days, and the differentiation capacities examined under either light or
fluorescence microscope (Nikon). For TNS cell differentiation, cells were incubated in
differentiation media with varying doses of triciribine (BioMol) or vehicle (DMSO, Sigma).
Knockdown of mouse c-Myc was performed by infecting the indicated cells with lentivirus
containing shMyc constructs (provided by Dr. William Hahn, Dana Farber Cancer Institute).
The shRNA constructs shMyc #1, #2 and #3 correspond to clone ID#s TRCN000000 54856,
42517 and 42513, respectively (The DFCI-Broad RNAi Consortium, commercially available
from Sigma-Aldrich).
Western, cell growth and self-renewal assays
Western blot assays were performed as previously described31 with antibodies against c-
Myc (sc-42, Santa Cruz), Phospho-AKTSer473 (9271, Cell signaling), Pten (9569, Cell
Signaling) and Actin (sc-1615, Santa Cruz). For in vitro cell growth assays, NSCs or TNS
cells (10,000) were plated in triplicate in 96-well format and incubated in NSC proliferation
media for 5 days, and growth was quantified using Luminescence ATP detection assay
system (PerkinElmer). Self-renewal capacity was measured by plating 1,000 cells/well (6-
well plate) in NSC proliferation media containing EGF/bFGF with 0.3% agarose (A9049,
Sigma). The number of neurospheres or tumor neurospheres that formed subsequently per
well was quantified after 10–14 days and relative sphere formation was plotted versus
indicated control. Three replicates were performed for each. All experiments were
conducted at cell passage <5.
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Female SCID (Charles River) aged 6–8 weeks were anesthetized and placed into stereotactic
apparatus equipped with a Z axis (Stoelting). A small hole was bored in the skull 0.5 mm
anterior and 3.0 mm lateral to the Bregma using a dental drill. 2×104 cells in Hanks Buffered
Salt Solution was injected into the right caudate nucleus 3 mm below the surface of the brain
using a 10 µl Hamilton syringe with an unbeveled 30 gauge needle. The scalp was closed
using a 9 mm Autoclip Applier. Animals were followed daily for development of
neurological deficits.
Mutation screening
Frozen tumor specimens were obtained from the Memorial Sloan Kettering Cancer Center
tumor bank. Genomic DNA was prepared from frozen primary GBM tumour samples using
the Qiagen genomic purification kit. Coding exons were PCR amplified and sequenced
using standard protocols at the Harvard Partners Center for Genetics and Genomics as
previously described33. All known single-nucleotide polymorphisms and synonymous
mutations were removed from the analysis in the current study. This study was approved by
the Institutional Review Board of the hospital.
Microarray analysis
Early passage wild-type and indicated mutant NSCs were incubated with NSC proliferation
media or differentiation media for 18 hours. RNA was isolated using Trizol (Invitrogen) and
the RNeasy mini kit (Qiagen). Gene expression profiling was performed utilizing the
Affymetrix 430 2.0 chips at DFCI Microarray core facility.
Promoter Analysis
Gene expressions were modeled using dChip software34. Sets of genes differentially
expressed pre- and post- differentiation induction were generated using the SAM statistic35,
with a cutoff of +/− 2.0. Promoter analysis on both these gene sets used the CisGenome
software (http://biogibbs.stanford.edu/~jihk/CisGenome/index.htm) to scan the 8 kb
upstream to 2kb downstream regions of these genes for the ~550 motifs in the TRANSFAC
12.1 database. Enrichment was measured against control regions at a comparable distance
from the transcription start sites of random genes.
Statistical analysis
Tumor-free survivals were analyzed using Graphpad Prism4. Statistical analyses were
performed using nonparametric Mann–Whitney test. Significance of enrichment in the
promoter analysis was computed based on Poisson distribution with Bonferroni correction.
Comparisons of cell growth, self-renewal and differentiation were performed using the
unpaired Student's t-test. For all experiments with error bars, standard deviation was
calculated to indicate the variation within each experiment and data, and values represent
mean ± s.d.
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Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. p53 and Pten inactivation cooperate to induce high-grade malignant gliomas
a, Kaplan-Meier tumor-free survival curves for mice of indicated genotypes as a function of
weeks.
b, Graph shows frequency and grade of gliomas vs. non-CNS malignancies observed in end-
stage of indicated mice from a. Asy* indicates neurological asymptomatic hGFAP-
Cre;P53lox/lox;Ptenlox/+ mice (n=15) sacrificed for non-CNS malignancies.
c, H&E histology and immunohistochemical staining of sections of WHO grade III and
grade IV malignant gliomas from hGFAP-Cre;P53lox/lox;Ptenlox/+ mice with antibodies
against Ki67, GFAP, and Nestin. Scale bar, 50 µm.
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tFigure 2. hGFAP-Cre;P53lox/lox;Ptenlox/+ gliomas mirror key features of human malignant
gliomas
a, Pten expression is completely extinguished in tumor cells. Sections of three independent
malignant gliomas were stained with H&E, and an anti-Pten antibody. Note “N” indicates
the adjacent normal regions of the tumor cells; the arrows point to Pten-positive vascular
cells embedded in the tumor.
b, Wild-type Pten allele is lost in glioma cells. Genomic DNA isolated from liver tissues and
brain tumor cells were subjected to PCR-based assays for genotyping Pten and p53 alleles.
Note “+” designates the Pten wild-type allele; “L” the conditional allele; and “D” the
inactivated form of the conditional allele after Cre-mediated recombination.
c, Immunohistochemical staining of mouse normal brain or glioma sections with antibodies
against activated p-AKT, p-S6 kinase, and VEGF.
d, TNS lines isolated from independent malignant gliomas were cultured in NSC medium or
differentiation medium and immuno-stained for Nestin, GFAP and Tuj1 as indicated. Scale
bar, 50 µm.
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tFigure 3. p53 and Pten coordinately regulate c-Myc protein level as well as NSC self-renewal and
differentiation
a, The number of neurospheres formed by p53/Pten double-null NSCs in culture is
significantly increased as compared to wild-type or singly null NSCs (*P < 0.001; n=3).
Values represent mean ± s.d. from three experiments.
b, The multi-lineage differentiation potential was impaired in double-null NSCs. Note “WF”
designates for white-field; N for Nestin (red); G for GFAP (green); T for Tuj-1 (red); O4
(red); D for DAPI (blue).
c, Combined inactivation of p53 and Pten in NSCs stimulates c-Myc protein expression.
d, Knockdown of c-Myc expression restores p53/Pten double-null NSCs differentiation
capacity. Lower panel, western blot of double-null NSC c-Myc protein expression after
infected with indicated lenti-shRNA. Note c-Myc expression in shMyc #2 and #3 infected
double-null cells is comparable to that in p53-null cells, and shMyc #1 as a control shows no
knockdown.
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tFigure 4. Attenuated c-Myc expression restores hGFAP-Cre;P53lox/lox;Ptenlox/+ TNS
differentiation potential and reduces tumorigenic potential
a, Inhibition of the AKT pathway by triciribine induces TNS cell differentiation. Two
independent TNS lines were cultured in 1% FBS in the absence or presence of triciribine (5
µM) for 7 days before being subjected to immuno-staining with antibodies against Nestin
(red), GFAP (Green) and Tuj1 (red).
b, Inhibition of the AKT pathway in TNS cells with triciribine attenuates their cellular c-
Myc expression.
c, Knockdown of c-Myc expression in TNS cells reduces their self-renewal potential
assessed by sphere formation (*P < 0.001, n=3). Values represent mean ± s.d. from three
experiments.
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td, ShRNA-mediated reduction of c-Myc expression in TNS cells sensitizes cells to
differentiation stimuli. Cells infected with control and indicated shRNA were incubated with
differentiation medium before subjected to indicated lineage marker analysis.
e, ShRNA-mediated reduction of c-Myc expression represses TNS tumorigenic potency in
orthotopically transplanted SCID mice.
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